GPIHBP1 Genotype

If your triglycerides have ever come back in the thousands, or if a family member has had unexplained pancreatitis tied to extreme triglyceride levels, the explanation may be written in a single gene most doctors never check. GPIHBP1 (glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1) is one of a small handful of genes that, when disrupted, can shut down your body's ability to clear fat from the bloodstream.

This test reads the sequence of your GPIHBP1 gene to look for inherited variants linked to severe high triglycerides and a condition called familial chylomicronemia syndrome. The result is fixed for life. Knowing it can reshape how aggressively you protect yourself from pancreatitis, even decades before symptoms appear.

What GPIHBP1 Actually Does

GPIHBP1 makes a small protein that sits on the inside lining of your tiny blood vessels (capillaries). Its job is to grab another protein, lipoprotein lipase (LPL), from the tissue side of the vessel wall and shuttle it to the blood side. Once LPL is in place, it acts like scissors, snipping triglycerides out of large fat-carrying particles called chylomicrons and VLDL (very low-density lipoprotein, the main fat-carrying particle made by the liver) so the energy inside can be used by your body.

When GPIHBP1 is broken, LPL never reaches the bloodstream. The scissors stay in the wrong room. Fat particles keep circulating instead of being broken down, and triglyceride levels can climb very high.

Familial Chylomicronemia Syndrome

The main condition tied to GPIHBP1 variants is familial chylomicronemia syndrome (FCS), a rare inherited disorder where fat clearance is severely impaired. People with two damaged copies of GPIHBP1 typically have markedly elevated fasting triglycerides, often many times higher than typical levels, along with low HDL cholesterol.

The inheritance pattern matters. Carrying one damaged copy of GPIHBP1 usually produces normal or only mildly elevated triglycerides. Inheriting one damaged copy from each parent is what produces the full syndrome. In families described in the research, heterozygous carriers had only mild fasting hypertriglyceridemia while two-copy carriers had relapsing pancreatitis and refractory chylomicronemia.

Pancreatitis Risk

The reason GPIHBP1 status matters clinically is acute pancreatitis. When triglyceride-rich particles flood the bloodstream, the pancreas can become inflamed, sometimes catastrophically. In a Mexican cohort of patients with primary hypertriglyceridemia, pancreatitis occurred in roughly one in five cases, and the first patient in that population identified with GPIHBP1 deficiency presented with this exact syndrome.

Recurrent pancreatitis is a hallmark of GPIHBP1-related disease. One sibling pair described in the literature, both homozygous for the G56R variant, had relapsing pancreatitis that was refractory to standard treatment. Knowing the genetic basis changes management, because conventional triglyceride-lowering drugs often do not work in this setting.

Why Standard Lipid Panels Miss This

A routine lipid panel shows triglyceride and cholesterol numbers, but it cannot tell you why those numbers behave the way they do. Two people with similarly high triglycerides may have completely different underlying causes. One may have polygenic high triglycerides driven by many small genetic effects plus diet. The other may have a single broken gene like GPIHBP1 that means dietary changes alone will never normalize their numbers.

In a study of adults with severe hypertriglyceridemia, only a small fraction had a clear single-gene cause identified through testing of GPIHBP1 and related genes, and another small fraction had an acquired antibody-based version of the condition. Most severe high triglycerides are polygenic or multifactorial, but the small group with a GPIHBP1 cause is the group most likely to need specialized care.

Types of GPIHBP1 Variants That Cause Disease

Pathogenic variants cluster in two regions of the gene. One region builds the part of the protein that grips LPL. Variants here, including changes that swap cysteine residues (the chemical building blocks that hold the protein's shape together), cause the protein to misfold or clump, so it can no longer bind LPL. The other region anchors the protein to the cell surface. Variants here cut the protein short or extend it abnormally, so it never reaches the surface at all.

Whole-gene deletions, where one or both copies of GPIHBP1 are missing entirely, have also been described. In a Korean family, compound heterozygous deletions of the gene caused severe chylomicronemia in siblings, a finding that standard sequencing alone could miss because deletions sometimes require additional analysis to detect.

One-Time Result, Lifelong Implications

Your GPIHBP1 genotype does not change. It is set at conception and stays the same in every cell for life. This is not a marker you retest to see if it has improved. The value comes from acting on the result, not repeating it.

If a pathogenic variant is found, the testing you do repeat is downstream. Triglyceride levels should be checked frequently to track the actual lipid burden your body is carrying, and a fasting lipid panel every few months is reasonable when you are working to reduce risk. If your initial test was done on a SNP chip or a screening panel, a confirmation test using a different sequencing method may be warranted before making major decisions.

What to Do With an Out-of-Pattern Result

If your test identifies a pathogenic GPIHBP1 variant, the next step is a focused workup with a lipid specialist or endocrinologist familiar with familial chylomicronemia. Companion testing typically includes a detailed fasting lipid panel with chylomicron assessment, an LPL activity measurement, and consideration of an autoantibody test for GPIHBP1, because a rare acquired form of the disease mimics the genetic one.

Because GPIHBP1-related disease is inherited in an autosomal recessive pattern, your biological siblings have a meaningful chance of also being affected or being carriers, and your children will inherit at least one variant copy from you. A genetic counselor can help map the implications for your family and decide who else should test. If your result is unexpectedly negative on a panel but clinical suspicion is high, ask whether copy-number analysis was included, since whole-gene deletions can be missed by standard sequencing.

When Results Can Be Misleading

• Variant panel coverage: the test only detects variants the assay is designed to look for. A negative result does not rule out rare variants in regions not covered, including some deep intronic changes or large deletions that require copy-number analysis.
• Variants of uncertain significance: sequencing sometimes turns up a change in your GPIHBP1 gene that has not been studied enough to know if it matters. These results require expert interpretation rather than action.
• Ancestry effects: specific variants are more common in some populations than others. A test designed around variants common in European populations may miss variants more frequent in Latin American, East Asian, or African ancestry, so test choice matters.
• Genetic vs acquired disease: a normal GPIHBP1 genotype does not rule out the autoantibody version of the disease, which can produce identical symptoms but is acquired rather than inherited. Antibody testing is a separate assay.

Who This Result Speaks To

GPIHBP1 testing is most useful for people whose lipid story does not fit a typical pattern: very high triglycerides at a young age, triglycerides that do not respond to standard medications and lifestyle changes, a history of unexplained pancreatitis, or a family history of chylomicronemia. For people with these features, the genotype answers a fundamental question about what is driving the numbers, and that answer shapes treatment for life.